Virtue Diagnostics is an innovative IVD company focusing on Infectious Disease, Cancer, Maternal & Fetal Health, and Chronic Disease.
Virtue's mission is to create a leading innovative global diagnostic company by leveraging diverse technology platforms through internal development and external collaboration.
Virtue Diagnostics was founded in China in 2019 by Johnson (Sheng) Zhang. The company is headquartered in Singapore, with manufacturing in Suzhou and CRO/Clinical Lab in Beijing.
Virtue Diagnostics uses its diverse technology platforms to provide clinical solutions for patients at all disease stages including early screening, initial diagnosis, treatment monitoring and minimal residual disease management.
Virtue Diagnostics has adopted a new collaborative model, which establishes a complete industrial chain from innovative research and development to clinical trials, clinical applications, and large-scale industrialization.
Virtue Diagnostics is backed by Lilly Asia Ventures, Sequoia Capital China, Morningside Ventures, ORIZA Holdings, PerkinElmer Ventures, and others. The company raised $100M in Series B round on Jan 06, 2022. This brings Virtue Diagnostics' total funding to $130M to date.